+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07552454

Study of Picankibart Treatment for Moderate-to-Severe Palmoplantar Pustulosis in Adults Aged 18 to 65

Led by Xijing Hospital · Updated on 2026-04-27

60

Participants Needed

1

Research Sites

11 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Picankibart in treating moderate-to-severe palmoplantar pustulosis, a skin condition characterized by pustules on the palms and soles. This is a prospective, single-arm, open-label clinical study conducted by the Department of Dermatology at the First Affiliated Hospital of Air Force Medical University, aiming to enroll 60 participants aged 18 to 65 years who have not adequately responded to or tolerated conventional systemic treatments. Participants receive Picankibart through subcutaneous injections in two phases. During the induction phase, Picankibart 200 mg is given at Weeks 0, 4, and 8. The maintenance phase follows with Picankibart 100 mg administered at Weeks 20, 32, and 44. There is no comparator group, and all participants receive the study drug openly without blinding. Throughout the study, participants will be monitored for changes in the Palmoplantar Pustular Psoriasis Area and Severity Index PPPASI at 16 weeks, which serves as the primary outcome measure. The study includes regular follow-up visits to assess treatment response, safety, and adherence. Participants may withdraw at any time, and safety will be closely observed for any adverse events during the trial period, which extends until the end of 2027.

CONDITIONS

Brief Title

Picankibart in Palmoplantar Pustulosis

Research Team

S

Shuai Shao

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here